Scivision BiotechTPE:1786 -0.56%80 Interest Coverage is 16.14 as of Dec. 2025, which is 23% below its 10-year median of 20.90. GuruFocus rates TPE:1786 with a GF Score™ of 80/100 and a GF Value™ of NT$115.23 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 465 Medical Devices & Instruments companies, Scivision Biotech ranks better than 58.06% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Scivision Biotech's
Operating Income
for the
three
months ended in Dec. 2025 was NT$49.9 Mil. Scivision Biotech's Interest Expense for the
three
months ended in Dec. 2025 was NT$-3.1 Mil.
Scivision Biotech's interest coverage for the quarter that ended in Dec. 2025 was 16.14.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Scivision Biotech's Interest Coverage or its related term are showing as below:
TPE:1786'
s Interest Coverage Range Over the Past 10 Years
Min: 5.42 Med: 20.9 Max: 43.74
Current: 23.95
TPE:1786's Interest Coverage is ranked better than 58.06% of 465
companies
in the Medical Devices & Instruments industry
Industry Median: 16.03
vs TPE:1786: 23.95
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Scivision Biotech Interest Coverage Related Terms
Scivision Biotech Interest Coverage Historical Data
* Premium members only.
The historical data trend for Scivision Biotech's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
TPE:1786 vs ISRG, BDX, MDLN: Interest Coverage Comparison
For the Medical Instruments & Supplies subindustry, Scivision Biotech's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scivision Biotech Interest Coverage vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Scivision Biotech's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Scivision Biotech's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scivision Biotech (TPE:1786) has a Interest Coverage of 16.14 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Scivision Biotech and its competitors. This is 23% below median its historical median of 20.90. Over the past decade, Scivision Biotech's Interest Coverage has ranged from 5.42 to 43.74. According to the industry distribution chart, Scivision Biotech ranks #195 out of 465 companies in the Medical Devices & Instruments industry, placing it in the top 41.9%.
Is Scivision Biotech's Interest Coverage too high?
Scivision Biotech's current Interest Coverage of 16.14 is 23% below median its 10-year median of 20.90. Over the past 10 years, this metric has ranged from a low of 5.42 to a high of 43.74. The Medical Devices & Instruments industry median Interest Coverage is 16.03. Scivision Biotech's value of 16.14 is 0.7% above this industry median. Based on the distribution chart, Scivision Biotech ranks #195 out of 465 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Scivision Biotech has a GF Score™ of 80/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Scivision Biotech's Interest Coverage compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Scivision Biotech ranks #195 out of 465 companies for Interest Coverage. This puts Scivision Biotech in the upper half of its industry. The industry median Interest Coverage is 16.03. Scivision Biotech's value of 16.14 is 0.7% above this benchmark. Historically, Scivision Biotech's own Interest Coverage has ranged from 5.42 to 43.74 over the past decade. While the company's 10-year median is 20.90 vs. the industry median of 16.03, Scivision Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Devices & Instruments company?
The median Interest Coverage among Medical Devices & Instruments companies is 16.03, based on 465 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scivision Biotech's current Interest Coverage of 16.14 is 0.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Scivision Biotech and its competitors. For the Medical Devices & Instruments industry, the median Interest Coverage is 16.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scivision Biotech's current Interest Coverage is 16.14, which is 23% below median its own 10-year median of 20.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scivision Biotech stock overvalued right now?
Based on GuruFocus' analysis, Scivision Biotech (TPE:1786) is currently considered Possible Value Trap. The stock's GF Value™ is NT$115.23, compared to a current price of NT$53.50 — trading 53.6% below its estimated fair value. The current Interest Coverage is 16.14, which is 23% below median its 10-year median of 20.90 and 0.7% above the Medical Devices & Instruments industry median of 16.03. Scivision Biotech's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Scivision Biotech (TPE:1786), the current Interest Coverage is 16.14 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scivision Biotech (TPE:1786) Overvalued in 2026?
Based on GuruFocus' analysis, Scivision Biotech stock appears to be undervalued.
The current stock price of NT$53.50 is trading 53.6% below its estimated GF Value™ of NT$115.23.
GuruFocus considers Scivision Biotech to be Possible Value Trap.
Key valuation signals for TPE:1786:
Interest Coverage: 16.14 (23% below median its 10-year median of 20.90)
GF Value™: NT$115.23 vs. price of NT$53.50 (53.6% below fair value)
Industry Position: 0.7% above the Medical Devices & Instruments median (#195 of 465)
No single metric tells the full story. See the TPE:1786 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scivision Biotech Inc is engaged in the manufacturing and distribution of hyaluronic acid medical supplies in Taiwan. It offers medical devices, including absorbable adhesion barriers, dermal implants, synovial fluid supplements, and intravesical instillation.
80GF Score
Get the complete analysis for TPE:1786
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1786 has been successfully added to your 
